Microbiological resistance of Candida to fluconazole: surveillance sampling · HIV‐positive people
Antifungal prophylaxis showed no clear difference in microbiological resistance of Candida to fluconazole: surveillance… compared with no antifungal prophylaxis (low certainty).
1 finding from 1 review
Treatment discontinuation · HIV‐positive people
Antifungal prophylaxis showed no clear difference in treatment discontinuation compared with no antifungal prophylaxis (moderate certainty).
1 finding from 1 review
Any serious adverse event · HIV‐positive people
Antifungal prophylaxis showed no clear difference in any serious adverse event compared with no antifungal prophylaxis (low certainty).
1 finding from 1 review
Any adverse events · HIV‐positive people
Antifungal prophylaxis showed no clear difference in any adverse events compared with no antifungal prophylaxis (low certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
Two weeks of AmBd + FLU + steroids showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (high certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
One week of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
One week of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
One week of AmBd + FLU probably leads to higher mortality: 10 weeks compared with two weeks of 5FC + FLU (moderate certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
It is very uncertain whether two weeks of FLU changes mortality: 10 weeks compared with two weeks of 5FC + FLU (very low certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
It is very uncertain whether two weeks of L‐AmB changes mortality: 10 weeks compared with two weeks of AmBd (very low certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
Short‐course L‐AmB + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of L‐AmB + FLU (low certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + 5FC (very low certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + FLU (very low certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd (very low certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
One week of AmBd + 5FC + FLU showed no clear difference in mortality: 10 weeks compared with one week of AmBd + FLU (low certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
Two weeks of AmBd + 5FC + IFNg showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (low certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with one week of AmBd + FLU (moderate certainty).
1 finding from 1 review
Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis
One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of 5FC + FLU (moderate certainty).
1 finding from 1 review